rs1306475361
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003002.4(SDHD):c.170-1G>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_003002.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHD | NM_003002.4 | c.170-1G>T | splice_acceptor_variant, intron_variant | Intron 2 of 3 | ENST00000375549.8 | NP_002993.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHD | ENST00000375549.8 | c.170-1G>T | splice_acceptor_variant, intron_variant | Intron 2 of 3 | 1 | NM_003002.4 | ENSP00000364699.3 | |||
ENSG00000255292 | ENST00000532699.1 | n.170-1G>T | splice_acceptor_variant, intron_variant | Intron 2 of 5 | 3 | ENSP00000456434.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251124Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135712
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary pheochromocytoma-paraganglioma Pathogenic:2
- -
This variant disrupts a canonical splice site and is predicted to result in abnormal splicing. Aberrant splicing and/or loss of function is an established mechanism of disease. This prediction has been confirmed by functional studies (PMID: 12509798, 29545045). This variant has been reported in multiple individuals with paragangliomas (PMID: 12509798, 18551016, 12114404, 19075037, 22566194, 29545045, 30877234, 32472550). This variant is present in 1/251124 total alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant has been reported to co-segregate with disease in more than one family (PMID: 12509798, 18551016, 32472550). -
Pheochromocytoma;C1847319:Carney-Stratakis syndrome;C1868633:Paragangliomas with sensorineural hearing loss;CN166604:Cowden syndrome 3 Pathogenic:1
This sequence change affects an acceptor splice site in intron 2 of the SDHD gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SDHD are known to be pathogenic (PMID: 19454582, 19802898). This variant is present in population databases (no rsID available, gnomAD 0.0009%). Disruption of this splice site has been observed in individual(s) with SDHD-related conditions (PMID: 12114404, 12509798, 18551016, 19075037, 22566194, 29545045, 30050099, 30877234). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 438434). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.170-1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide upstream from coding exon 3 of the SDHD gene. This alteration has been identified in numerous patients from multiple ethnic groups with unilateral or bilateral carotid body tumors, both with and without a family history of pheochromocytomas and/or paragangliomas (Dannenberg H et al. Clin. Cancer Res. 2002 Jul;8:2061-6; Persu A et al. J. Hypertens. 2008 Jul;26:1395-401; Renard L et al. Head Neck. 2003 Feb;25:146-51; Zuo Y et al. Urology. 2018 06;116:63-67; Santi R et al. Anticancer Res. 2017 02;37:805-812; Piccini V et al. Endocr. Relat. Cancer. 2012 Apr;19:149-55; Burnichon N et al. J. Clin. Endocrinol. Metab. 2009 Aug;94:2817-27; Astrom K et al. Hum. Genet. 2003 Aug;113:228-37; Benn DE et al. J. Clin. Endocrinol. Metab. 2006 Mar;91:827-36). This alteration was also identified in a patient with a glomus tumor (Mannelli M et al. Ann. N. Y. Acad. Sci. 2006 Aug;1073:183-9), a patient with bilateral carotid body tumors and a primary mediastinal paraganglioma (Ghayee HK et al. Endocr. Relat. Cancer. 2009 Mar;16:291-9;), and patients with cervical paragangliomas (Bauters C et al. J. Med. Genet. 2003 Jun;40:e75). Of note, this alteration is also designated as IVS2-1G>T in the published literature. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at